Last reviewed · How we verify

Levofloxacin only

Innocoll · Phase 2 active Small molecule

Levofloxacin only is a Fluoroquinolone antibiotic Small molecule drug developed by Innocoll. It is currently in Phase 2 development for Community-acquired pneumonia, Skin and skin structure infections, Complicated urinary tract infections. Also known as: Tavanic, Levaquin.

Inhibits DNA gyrase and topoisomerase IV

Inhibits DNA gyrase and topoisomerase IV Used for Community-acquired pneumonia, Skin and skin structure infections, Complicated urinary tract infections.

Likelihood of approval
17.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Anti-infectives pathway favourability +2.0pp
    Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameLevofloxacin only
Also known asTavanic, Levaquin
SponsorInnocoll
Drug classFluoroquinolone antibiotic
TargetDNA gyrase and topoisomerase IV
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 2

Mechanism of action

Levofloxacin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication and transcription.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levofloxacin only

What is Levofloxacin only?

Levofloxacin only is a Fluoroquinolone antibiotic drug developed by Innocoll, indicated for Community-acquired pneumonia, Skin and skin structure infections, Complicated urinary tract infections.

How does Levofloxacin only work?

Inhibits DNA gyrase and topoisomerase IV

What is Levofloxacin only used for?

Levofloxacin only is indicated for Community-acquired pneumonia, Skin and skin structure infections, Complicated urinary tract infections.

Who makes Levofloxacin only?

Levofloxacin only is developed by Innocoll (see full Innocoll pipeline at /company/innocoll).

Is Levofloxacin only also known as anything else?

Levofloxacin only is also known as Tavanic, Levaquin.

What drug class is Levofloxacin only in?

Levofloxacin only belongs to the Fluoroquinolone antibiotic class. See all Fluoroquinolone antibiotic drugs at /class/fluoroquinolone-antibiotic.

What development phase is Levofloxacin only in?

Levofloxacin only is in Phase 2.

What are the side effects of Levofloxacin only?

Common side effects of Levofloxacin only include Nausea, Diarrhea, Headache.

What does Levofloxacin only target?

Levofloxacin only targets DNA gyrase and topoisomerase IV and is a Fluoroquinolone antibiotic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing